Literature data reporting SARS-CoV-2 infection in multiple sclerosis (MS) patients recently treated with immunodepleting agents as cladribine and alemtuzumab are very limited. The relationship between iatrogenic immunodeficiency and risk related to SARS-CoV-2 infection and its severe complications is still not clear. Cautiously, the start of immunosuppressant drugs as alemtuzumab and cladribine during the current COVID-19 pandemic is not recommended unless treatment benefits significantly outweigh potential risks. We report the case of a 30-year-old female MS patient infected by SARS-CoV-2 virus 4 months after alemtuzumab II cycle, while she was still leukopenic and lymphopenic. She had no complications and also presented milder COVID-related signs and symptoms as compared to her coinfected relatives (father, mother and her partner). Anti-S1 and S2 SARS-CoV-2 antibodies, tested 1 month and a half after the infection, resulted positive. We review all cases reported in literature of SARS-CoV-2 infection in MS patients treated with alemtuzumab. None of them had complications or severe disease.

最近使用免疫耗竭剂如克拉屈滨和阿仑单抗治疗的多发性硬化症 (MS) 患者中报告 SARS-CoV-2 感染的文献数据非常有限。医源性免疫缺陷与 SARS-CoV-2 感染及其严重并发症相关风险之间的关系尚不清楚。谨慎地说，不建议在当前 COVID-19 大流行期间开始使用阿仑单抗和克拉屈滨等免疫抑制药物，除非治疗益处显着超过潜在风险。我们报告了一名 30 岁女性 MS 患者在阿仑单抗 II 周期后 4 个月感染 SARS-CoV-2 病毒的病例，而她仍处于白细胞减少和淋巴细胞减少的状态。与她的共同感染亲属（父亲、母亲和她的伴侣）相比，她没有并发症，并且与 COVID 相关的体征和症状也较轻。抗 S1 和 S2 SARS-CoV-2 抗体在感染后 1 个半月进行测试，结果呈阳性。我们回顾了文献中报道的所有接受阿仑单抗治疗的 MS 患者感染 SARS-CoV-2 的病例。他们都没有并发症或严重疾病。